Larsa Pippen opened up about her changed appearance by clapping back at a doctor who claimed she had ‘excessive facial filler ...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that Health Canada has granted a marketing ...

A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...

Astria will receive $16m upfront and is eligible for a further $16m in commercialisation and sales milestones.

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations. The FDA maintained its momentum in July, issuing a wave of drug approvals across diverse ...

As clinicians and patient representatives, we see firsthand the challenges faced by people living with hereditary angioedema, ...

Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating ...

A real-world study published in the International Archives of Allergy and Immunology found that 3 years of lanadelumab ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) is one of the best mid cap pharma stocks to buy. On July 21, Ionis Pharmaceuticals announced that positive results from the Phase 3 OASISplus prospective ...

Astria took the candidate, a monoclonal antibody inhibitor of plasma kallikrein called navenibart, into a late-stage study off the back of a phase 1b/2 trial last year that tied the drug to up to a 92 ...

The following are notable drug approvals for July 2025.